Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Actuate Therapeutics, Inc. - Common stock (NQ:ACTU)

2.960 -0.100 (-3.27%)
Streaming Delayed Price Updated: 1:52 PM EST, Mar 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Actuate Therapeutics, Inc. - Common stock

News headline image
Actuate Therapeutics Stock Rises After Updating FDA Application For Lead Investigational Drug In Treating Pancreatic Cancer ↗
Actuate on Monday also said that its recent $17.25 million public offering provides an extended runway into the second half of 2026. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
This Actuate Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Pheton, Powell Max Make Public Debut ↗
Pheton Holdings and Powell Max opened for trading on Thursday at $3.76 and $4.30, respectively. While the number of initial public offerings has rebounded from 2023, IPOs remain well below pre-pandemic... 
Via Talk Markets
News headline image
Actuate Therapeutics Makes Public Debut ↗
Actuate Therapeutics opened on Aug. 13 at $9.88. The biopharmaceutical company had priced its initial public offering of 2.8 million shares at a price of $8.00 per share. 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.